

1 **Title: Net Clinical Benefit of Edoxaban for 12 versus 3 Months in Cancer-associated**  
2 **Isolated Distal Deep Vein Thrombosis: ONCO DVT study**

3  
4 **Authors:** Yuji Nishimoto, MD<sup>1,2</sup>; Yugo Yamashita, MD<sup>3</sup>; Takeshi Morimoto, MD, MPH<sup>4</sup>;  
5 Nao Muraoka, MD<sup>5</sup>; Michihisa Umetsu, MD<sup>6</sup>; Takuma Takada, MD<sup>7</sup>; Yoshito Ogihara, MD<sup>8</sup>;  
6 Tatsuya Nishikawa, MD<sup>9</sup>; Nobutaka Ikeda, MD<sup>10</sup>; Kazunori Otsui, MD<sup>11</sup>; Daisuke Sueta,  
7 MD<sup>12</sup>; Yukari Tsubata, MD<sup>13</sup>; Masaaki Shoji, MD<sup>14</sup>; Ayumi Shikama, MD<sup>15</sup>; Yutaka Hosoi,  
8 MD<sup>16</sup>; Yasuhiro Tanabe, MD<sup>17</sup>; Ryuki Chatani, MD<sup>18</sup>; Kengo Tsukahara, MD<sup>19</sup>; Naohiko  
9 Nakanishi, MD<sup>20</sup>; Kitae Kim, MD<sup>21</sup>; Satoshi Ikeda, MD<sup>22</sup>; Yukihiro Sato, MD<sup>2</sup>; Tetsuya  
10 Watanabe, MD<sup>1</sup>; Takahisa Yamada, MD<sup>1</sup>; Masatake Fukunami, MD<sup>1</sup>; Takeshi Kimura, MD<sup>23</sup>;  
11 On behalf of the ONCO DVT Study Investigators.

12  
13 **Affiliations:** <sup>1</sup>Division of Cardiology, Osaka General Medical Center, Osaka, Japan.  
14 <sup>2</sup>Department of Cardiology, Hyogo Prefectural Amagasaki General Medical Center,  
15 Amagasaki, Japan. <sup>3</sup>Department of Cardiovascular Medicine, Graduate School of Medicine,  
16 Kyoto University, Kyoto, Japan. <sup>4</sup>Department of Clinical Epidemiology, Hyogo Medical  
17 University, Nishinomiya, Japan. <sup>5</sup>Division of Cardiology, Shizuoka Cancer Center, Shizuoka,  
18 Japan. <sup>6</sup>Division of Vascular Surgery, Department of Surgery, Tohoku University Hospital,  
19 Sendai, Japan. <sup>7</sup>Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan.  
20 <sup>8</sup>Department of Cardiology and Nephrology, Mie University Graduate School of Medicine,  
21 Tsu, Japan. <sup>9</sup>Department of Onco-Cardiology, Osaka International Cancer Institute, Osaka,  
22 Japan. <sup>10</sup>Division of Cardiovascular Medicine, Toho University Ohashi Medical Center,  
23 Tokyo, Japan. <sup>11</sup>Department of General Internal Medicine, Kobe University Graduate School  
24 of Medicine, Kobe, Japan. <sup>12</sup>Department of Cardiovascular Medicine, Graduate School of  
25 Medical Sciences, Kumamoto University, Kumamoto, Japan. <sup>13</sup>Department of Internal  
26 Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 Faculty of Medicine, Izumo, Japan. <sup>14</sup>Department of Cardiovascular Medicine, National  
2 Cancer Center Hospital, Tokyo, Japan. <sup>15</sup>Department of Obstetrics and Gynecology, Faculty  
3 of Medicine, University of Tsukuba, Tsukuba, Japan. <sup>16</sup>Department of Cardiovascular Surgery,  
4 Kyorin University Faculty of Medicine, Tokyo, Japan. <sup>17</sup>Department of Cardiology, St.  
5 Marianna University School of Medicine, Kawasaki, Japan. <sup>18</sup>Department of Cardiovascular  
6 Medicine, Kurashiki Central Hospital, Kurashiki, Japan. <sup>19</sup>Division of Cardiology, Fujisawa  
7 City Hospital, Fujisawa, Japan. <sup>20</sup>Department of Cardiovascular Medicine, Graduate School  
8 of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. <sup>21</sup>Department  
9 of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.  
10 <sup>22</sup>Department of Cardiovascular Medicine, Nagasaki University Graduate School of  
11 Biomedical Sciences, Nagasaki, Japan. <sup>23</sup>Department of Cardiology, Hirakata Kohsai  
12 Hospital, Hirakata, Japan.

13

14 **Short title:** Net clinical benefit of Edoxaban: ONCO DVT study

15

16 **Address for correspondence:** Yuji Nishimoto, MD

17 Division of Cardiology, Osaka General Medical Center

18 3-1-56, Mandai-Higashi, Sumiyoshi-ku, Osaka 558-8558, Japan

19 TEL: +81-6-6692-1201 FAX: +81-6-6606-7000 E-mail: [yuji.nishimoto@gmail.com](mailto:yuji.nishimoto@gmail.com)

1 **Abstract**

2 **Background:** The ONCO DVT (Edoxaban for 12 Months Versus 3 Months in Patients With  
3 Cancer With Isolated Distal Deep Vein Thrombosis) study has revealed the superiority of a  
4 12-month versus 3-month edoxaban treatment in terms of fewer thrombotic events for  
5 cancer-associated isolated distal deep vein thrombosis; however, concern for increased  
6 bleeding with longer anticoagulation remains.

7 **Methods:** In this post-hoc analysis of the ONCO DVT study, we compared 12-month and  
8 3-month edoxaban treatments in terms of the net adverse clinical events (NACE) as a  
9 composite endpoint of the primary endpoint (symptomatic recurrent VTE and VTE-related  
10 death at 12 months) and major secondary endpoint (major bleeding at 12-months) of the  
11 ONCO DVT study. The net clinical benefit of a 12-month over 3-month treatment was  
12 defined as the sum of the differences in the incidence of thrombotic and bleeding events  
13 between the 3- month and 12-month treatments. The weight of bleeding events was set at 1.0,  
14 and we assessed the changes in the net clinical benefit with weights of bleeding events set at  
15 0.5 and 2.0.

16 **Results:** With a weight of bleeding events of 1.0, NACE occurred in 30 of 296 patients  
17 (10.1%) in the 12-month edoxaban group and in 42 of 305 patients (13.8%) in the 3-month  
18 edoxaban group. The net clinical benefit was 3.6% (95% CI, -1.5% to 8.8%). There was a  
19 significant treatment-by-subgroup interaction between the thrombocytopenia or cancer  
20 metastasis subgroup factors and the effect of the 12-month relative to the 3-month treatment  
21 for NACE. As the weights of bleeding events changed from 0.5 to 2.0, the net clinical benefit  
22 in the 12-month edoxaban group as compared to the 3-month edoxaban group became  
23 attenuated from 4.8% (95% CI, 0.5% to 9.0%) to 0.7% (95% CI, -5.7% to 7.1%).

24 **Conclusions:** The net clinical benefit of the 12-month over 3-month edoxaban treatment was  
25 not significant; however, the 12-month treatment had a numerically lower incidence of  
26 NACE than the 3-month treatment.

1

2 **Clinical Trial Registration:** ClinicalTrials.gov, NCT03895502.

3

4 **Keywords:** venous thrombosis; neoplasms; edoxaban; hemorrhage; recurrence

## 1 **Clinical Perspective**

### 2 **What is new?**

- 3 ● The net clinical benefit of the 12-month over 3-month edoxaban treatment was not  
4 significant in terms of the net clinical adverse events (NACE) combined with  
5 symptomatic recurrent venous thromboembolism (VTE), VTE-related death, or major  
6 bleeding with a weight of bleeding events of 1.0, however, the 12-month group had a  
7 numerically lower incidence of the NACE than the 3-month group.
- 8 ● The net clinical benefit of the 12-month over 3-month edoxaban treatment became  
9 attenuated as the weights of the bleeding events increased.

10

### 11 **What are the clinical implications?**

- 12 ● The present study revealed that the 12-month edoxaban treatment compared with the  
13 3-month edoxaban treatment was basically favorable in terms of NACE; however, the  
14 net clinical benefit of the 12-month edoxaban treatment became attenuated as the  
15 weights of the bleeding events increased.
- 16 ● Further studies should be required to evaluate the case fatality rate of each event and its  
17 impact on cancer treatment.

18

19

20

21

22

23

24

25

26

## 1 **Introduction**

2 Cancer-associated venous thromboembolism (VTE) is a major concern in the cancer  
3 trajectory because it is one of leading causes of death in patients with cancer and also can  
4 interrupt or delay cancer treatment.<sup>1,2</sup> In addition, the incidence of cancer-associated VTE has  
5 increased in recent years due to an improved prognosis in patients with cancer, increased use  
6 of thrombogenic anticancer-drugs, growing awareness of cancer-associated thrombosis, and  
7 more frequent imaging tests for cancer assessments.<sup>1,3-5</sup> Recent randomized controlled trials  
8 comparing direct oral anticoagulants (DOACs) with low-molecular-weight heparin have  
9 revealed that DOACs could be a potential treatment option for cancer-associated VTE, which  
10 has resulted in a paradigm shift in the treatment strategies.<sup>6-11</sup> Given the long-term high risk  
11 of recurrence in patients with cancer-associated VTE,<sup>12</sup> the latest guidelines recommend  
12 prolonged anticoagulation therapy including DOACs for these patients.<sup>13-16</sup> However,  
13 patients with cancer also have a high risk of bleeding during anticoagulation therapy, leading  
14 to a challenge in achieving a risk-benefit balance with anticoagulation therapy.<sup>17</sup>

15         The recent ONCO-DVT (Edoxaban for 12 Months Versus 3 Months in Patients With  
16 Cancer With Isolated Distal Deep Vein Thrombosis) study showed the potential benefit of  
17 extended anticoagulation therapy with edoxaban in patients with cancer and isolated distal  
18 deep vein thrombosis (DVT), whereas it also suggested a potential signal for an increased  
19 risk of bleeding with a longer duration of edoxaban treatment.<sup>18</sup> It would be clinically  
20 relevant to consider the risk-benefit balance of the duration of anticoagulation therapy in  
21 cancer-associated VTE. Therefore, we conducted a post-hoc analysis on an exploratory basis  
22 to compare the net adverse clinical events (NACE) combining thrombotic and bleeding  
23 events between a 12-month and a 3-month edoxaban treatment in patients with  
24 cancer-associated isolated distal DVT using the ONCO DVT study database.

25

## 26 **Methods**

## 1 *Design and ethical statements*

2 The ONCO DVT study was an investigator-initiated, multicenter, open-label,  
3 adjudicator-blinded, superiority, randomized controlled trial conducted at 60 institutions in  
4 Japan that was designed to compare 12-month and 3-month edoxaban treatment regimens in  
5 patients with cancer and isolated distal DVT.<sup>18</sup> The details of the study organization and  
6 participating centers are provided in **Supplementary Appendix 1** and **2**, respectively. The  
7 full details of the ONCO DVT study were previously described.<sup>18</sup> Briefly, patients with active  
8 cancer who were newly diagnosed with isolated distal DVT using ultrasonography were  
9 randomly assigned, in a 1-to-1 ratio, either to the 12-month or 3-month edoxaban treatment  
10 groups. The study was conducted in accordance with the amended Declaration of Helsinki  
11 and was approved by the Kyoto University Institutional Review Board and the institutional  
12 review boards of all participating centers.

## 13 *Study population and treatment*

14 From April 2019 to June 2022, 604 patients were randomized. After excluding 3 patients who  
15 withdrew consent during follow-up, 601 patients were included in the present study.

16 Edoxaban was administered after an appropriate initial treatment after the diagnosis,  
17 in accordance with the policies at each institution. No restrictions were set for the policies,  
18 providing the treatment did not contravene the exclusion criteria. In the study protocol,  
19 edoxaban was recommended to be administered at a reduced dose of 30 mg once daily in  
20 patients with a creatinine clearance of 30 to 50 ml per minute or a body weight of 60 kg or  
21 less or in those receiving concomitant treatment with potent P-glycoprotein inhibitors.

## 22 *Patient characteristics and definitions*

23 Active cancer was defined as cancer meeting one of the following criteria: newly diagnosed  
24 within 6 months of randomization; cancer treatment (such as surgery, chemotherapy, or  
25 radiotherapy) performed within 6 months of randomization; currently receiving cancer  
26 treatment (such as surgery, chemotherapy, or radiotherapy); having a recurrence, local

1 invasion, or distant metastases, or patients with a hematopoietic malignancy who had not  
2 achieved a complete remission.<sup>6</sup> Definitions of the other baseline characteristics are provided  
3 in **Supplementary Appendix 3**.

#### 4 *Clinical outcomes and definitions*

5 In the ONCO DVT study, the primary endpoint was a composite of symptomatic recurrent  
6 VTE and VTE-related deaths at 12 months.<sup>18</sup> The major secondary endpoint was a major  
7 bleeding event at 12 months, and other secondary endpoints were symptomatic recurrent  
8 VTE events, VTE-related deaths, asymptomatic recurrent VTE events, all clinically relevant  
9 bleeding events, and all-cause deaths. Symptomatic recurrent VTE was defined as new or  
10 recently worsening pulmonary embolism (PE) or DVT symptoms, new thrombi found on  
11 imaging tests, or worsening thrombi compared to the most recent image. Symptomatic VTE  
12 recurrences were not determined solely based on the appearance or worsening thrombus  
13 images without any new or worsening symptoms. Similarly, if a patient had a thrombus in an  
14 index vein with new symptoms, it was not considered as symptomatic recurrent VTE unless a  
15 thrombus extension was present. VTE-related deaths were diagnosed at autopsy, following  
16 clinically severe PE or death not explained by something other than PE. Major bleeding was  
17 defined according to the International Society on Thrombosis and Haemostasis criteria, which  
18 was comprised of fatal bleeding, symptomatic bleeding in a critical area or organ, and  
19 bleeding reducing the hemoglobin levels by  $\geq 2$  g/dL or requiring transfusions of  $\geq 2$  units of  
20 whole blood or red cells.<sup>19</sup> Asymptomatic recurrent VTE was defined as the appearance of  
21 new or worsening thrombus images in the pulmonary arteries or deep veins on imaging tests  
22 that did not match the definition of a symptomatic VTE recurrence and were not associated  
23 with new or worsening symptoms. All clinically relevant bleeding events included major and  
24 non-major bleeding events. Clinically relevant non-major bleeding was defined as clinically  
25 overt bleeding (including bleeds detected only using imaging) not meeting the criteria for  
26 major bleeding, yet that led to one or more of the following: physician-guided medical



1 intervention, hospital admission or further treatment for bleeding, or an in-person medical  
2 examination by a physician. The members of an independent clinical outcomes committee  
3 who were unaware of the study-group assignments adjudicated all the suspected outcome  
4 events and causes of death, as well as the severity of the major bleeding events, with the use  
5 of prespecified criteria. The details of the definitions of the other endpoints are described in  
6 **Supplementary Appendix 4.**

7 In the present study, we assessed the risk-benefit balance of a 12-month versus  
8 3-month edoxaban treatment by combining the thrombotic and bleeding events into the  
9 NACE. If both thrombotic and bleeding events occurred during the observation period, the  
10 first event was considered NACE. We defined NACE-1 as a composite endpoint of the  
11 primary endpoint (symptomatic recurrent VTE and VTE-related death at 12 months) and  
12 major secondary endpoint (major bleeding at 12 months) of the ONCO DVT study. In  
13 addition, to assessing the broader spectrum of thrombotic and bleeding events, we defined  
14 NACE-2 as a composite endpoint of symptomatic recurrent VTE, VTE-related death,  
15 asymptomatic recurrent VTE, or all clinically relevant bleeding at 12 months.

16 The net clinical benefit of the 12-month over 3-month edoxaban treatment was  
17 defined as the sum of the differences in the incidence of thrombotic and bleeding events  
18 between the 3- and 12-month edoxaban treatments.<sup>21</sup> The net clinical benefit of the 12-month  
19 over 3-month edoxaban treatment was calculated as follows: incidence of thrombotic events  
20 (3-month edoxaban treatment – 12-month edoxaban treatment) + incidence of bleeding events  
21 (3-month edoxaban treatment – 12-month edoxaban treatment) × bleeding weight.<sup>21</sup> The net  
22 clinical benefit-1 and net clinical benefit-2 corresponded to NACE-1 and NACE-2,  
23 respectively. We set the weight of bleeding events as 1.0 in the base case analyses.

#### 24 ***Statistical analysis***

25 The categorical variables are presented as numbers and percentages and continuous variables  
26 as the mean with the standard deviation or median with the interquartile range based on their

1 distributions.

2           The analysis of the NACE was performed in the intention-to-treat population,  
3 which included all the patients who had undergone randomization after excluding those  
4 patients who withdrew consent. For patients who did not experience an event, the time to the  
5 first event was censored at day 365, or the last day the patient had a complete assessment for  
6 the study outcomes, whichever came first. Patients lost to follow-up and patients who died  
7 because of reasons other than VTE before the end of the 12-month treatment period and who  
8 did not achieve the endpoints, were censored on the last day when the patient had a complete  
9 assessment for the study outcomes. We compared the rates of patients with NACE between  
10 the 2 treatment groups in the intention-to-treat population and calculated the odds ratios (OR)  
11 with the corresponding 95% confidence intervals (CI) using the logistic regression models.  
12 The cumulative incidence was estimated using the Kaplan-Meier method, and the differences  
13 between the 2 groups were compared using the log-rank test. We also performed subgroup  
14 analyses with interaction tests in the prespecified clinically relevant subgroups as well as in  
15 the subgroups according to the symptom at diagnosis, which might have had some influence  
16 on the thrombotic outcomes. We constructed the same logistic regression models to estimate  
17 the P-values for any interaction in the subgroup analyses.

18           To explore the clinical importance of the bleeding events relative to the thrombotic  
19 events, we calculated the net clinical benefit with the weight of bleeding events set at 0.5 and  
20 2.<sup>21</sup>

21           All reported P values were two-sided and we considered a P <0.05 as statistically  
22 significant. All analyses were performed using STATA/SE 17.0 software (StataCorp) and R  
23 software version 4.2.2 (R Foundation for Statistical Computing, Vienna, Austria).

24

## 25 **Results**

### 26 *Patient characteristics*

1 Among the 601 patients included in the present study, there were 296 patients in the  
2 12-month edoxaban group and 305 in the 3-month edoxaban group. The clinical  
3 characteristics of the patients at baseline are shown in **Table 1**. The mean age was 70.8 years,  
4 28% of the patients were men, and 20% of the patients had symptoms of DVT at baseline.

### 5 *Base case analyses*

6 With a weight of bleeding events of 1.0, NACE-1, as a composite of symptomatic recurrent  
7 VTE, VTE-related deaths, or major bleeding, occurred in 30 patients (10.1%) in the  
8 12-month edoxaban group and 42 (13.8%) in the 3-month edoxaban group (Log-rank  $P=0.18$ ;  
9 OR 0.71; 95% CI, 0.43 to 1.16) (**Figure 1A and Table 2**). The net clinical benefit-1 of the  
10 12-month over 3-month edoxaban treatment was 3.6% (95% CI, -1.5% to 8.8%).

11 NACE-2, as a composite of symptomatic recurrent VTE, VTE-related deaths,  
12 asymptomatic recurrent VTE, or all clinically relevant bleeding, occurred in 69 patients  
13 (23.3%) in the 12-month edoxaban group and 95 (31.1%) in the 3-month edoxaban group  
14 (Log-rank  $P=0.047$ ; OR 0.67; 95% CI, 0.47 to 0.97) (**Figure 1B and Table 2**). The net  
15 clinical benefit-2 of the 12-month over 3-month edoxaban treatment was 7.8% (95% CI,  
16 0.8% to 14.9%). (**Figure 1B**).

### 17 *Subgroup analyses*

18 There was no treatment-by-subgroup interaction between the subgroups (pre-specified and  
19 presence of symptoms at the time of the diagnosis) and the effect of the 12-month versus  
20 3-month edoxaban treatment for NACE-1, except for those subgroups stratified by the  
21 platelet count and cancer metastasis (**Figure 2**). The 12-month edoxaban group had a higher  
22 risk of NACE-1 than the 3-month edoxaban group among the patients with thrombocytopenia  
23 (platelet count  $<100,000/\mu\text{l}$ ) (OR 12.9; 95% CI, 1.27 to 131) but a lower risk of NACE-1  
24 among the patients without thrombocytopenia (OR 0.58; 95% CI, 0.34 to 0.98) with a  
25 significant interaction ( $P=0.01$ ). The 12-month edoxaban group had a lower risk of NACE-1  
26 than the 3-month edoxaban group among the patients with cancer metastases (OR 0.34; 95%

1 CI, 0.14 to 0.81) but not among the patients without cancer metastases (OR 1.15; 95% CI,  
2 0.61 to 2.19), and there was a significant interaction (P=0.03) (**Figure 2** and **Supplementary**  
3 **Table S1**).

#### 4 *Effects of the weights of bleeding events on the net clinical benefit*

5 The net clinical benefit according to the weights of bleeding events is shown in **Figure 3**. As  
6 the weights of bleeding events increased from 0.5 to 2, the net clinical benefit-1 of the  
7 12-month over 3-month edoxaban treatment became attenuated from 4.8% (95% CI, 0.5% to  
8 9.0%) to 0.7% (95% CI, -5.7% to 7.1%) (**Figure 3A**). As the weights of bleeding events  
9 increased from 0.5 to 2, the net clinical benefit-2 of the 12-month over 3-month edoxaban  
10 treatment became attenuated from 10.1% (95% CI, 3.7% to 16.4%) to 3.1% (95% CI, -4.8%  
11 to 11.0%) (**Figure 3B**).

12

#### 13 **Discussion**

14 The main findings in the present study were as follows: 1) the net clinical benefit of the  
15 12-month over 3-month edoxaban treatment was not significant in terms of NACE-1  
16 combined with symptomatic recurrent VTE, VTE-related death, or major bleeding with a  
17 weight of bleeding events of 1.0; however, the 12-month group had a numerically lower  
18 incidence of NACE-1 than the 3-month group; 2) in terms of NACE-2 by adding  
19 asymptomatic VTE and clinically relevant non-major bleeding to the NACE-1, the net  
20 clinical benefit of the 12-month over 3-month edoxaban treatment was significant with a  
21 weight of bleeding events of 1.0; 3) the net clinical benefit of the 12-month over 3-month  
22 edoxaban treatment became attenuated as the weights of the bleeding events increased; and 4)  
23 there was a significant interaction between the subgroups stratified by thrombocytopenia and  
24 cancer metastasis and the effect of the 12-month relative to the 3-month edoxaban treatment  
25 for NACE.

26 The ONCO DVT study showed a numerically higher incidence of major bleeding in

1 the 12-month edoxaban treatment (9.5% vs. 7.2%) than in the 3-month edoxaban treatment  
2 groups.<sup>18</sup> Those incidences of major bleeding at 12 months were higher than that in the  
3 Hokusai VTE Cancer trial in the edoxaban treatment group (6.9%),<sup>6</sup> which was partly  
4 because the patients in the ONCO DVT study were older and more frequently had renal  
5 dysfunction than those in the Hokusai VTE Cancer trial. Because the primary endpoint of the  
6 Hokusai VTE Cancer trial was a composite of recurrent VTE or major bleeding, it may be  
7 clinically relevant to consider the risk-benefit balance with anticoagulation therapy by  
8 assessing the NACE combining thrombotic and bleeding events.<sup>22</sup> In contrast, there are  
9 well-known problems with using composite outcome measures simply as a combination of  
10 each event, such as the different clinical importance of each event.<sup>23</sup> Thus, it would be  
11 important to weigh each event in terms of the case fatality rate and impact on daily life.<sup>21-23</sup>  
12 Given the lack of the established weights of events occurring during anticoagulation therapy  
13 for VTE, the present study assessed the net clinical benefit using several weights and  
14 different composite endpoints on an exploratory basis. The present study revealed that the  
15 12-month edoxaban treatment compared with the 3-month edoxaban treatment was basically  
16 favorable in terms of NACE; however, the net clinical benefit of the 12-month edoxaban  
17 treatment became attenuated as the weights of the bleeding events increased. Further studies  
18 should be required to evaluate the case fatality rate of each event and its impact on cancer  
19 treatment.

20 The present study also showed different effects on the NACE in the subgroups of  
21 thrombocytopenia and cancer metastasis. Patients with VTE and thrombocytopenia had a  
22 higher risk of major bleeding both in patients receiving warfarin and in those receiving  
23 DOACs, especially in the first 3 months of the anticoagulation therapy.<sup>24-26</sup> Patients with  
24 thrombocytopenia in the present study also had a higher risk of major bleeding in the  
25 12-month edoxaban group than in the 3-month edoxaban group, but they had a low risk of  
26 thrombotic events in both groups, suggesting the 3-month edoxaban treatment may be

1 beneficial in patients with thrombocytopenia. On the other hand, the previous study showed  
2 that the effects of thrombocytopenia on major bleeding may be attenuated in patients with  
3 cancer-associated VTE.<sup>26</sup> Considering the small absolute number of patients with  
4 thrombocytopenia in the ONCO DVT study, cautious interpretation would be warranted. For  
5 patients with VTE and cancer metastases, the current guidelines recommend prolonged  
6 anticoagulation therapy beyond 6 months due to a high risk of VTE recurrence, but  
7 supporting evidence is scarce.<sup>2,15</sup> Those patients also had a high risk of major bleeding during  
8 anticoagulation therapy.<sup>27</sup> The present study showed numerically higher incidences of both  
9 thrombotic and bleeding events in patients with cancer metastases than in those without  
10 cancer metastases and indicated a potential net clinical benefit of the 12-month over 3-month  
11 edoxaban treatment.

12 The present study had several limitations. First, the open-label design had the  
13 potential to introduce bias, including ascertainment bias. However, all clinical endpoints were  
14 adjudicated by the members of an independent committee who were blinded to the study  
15 group assignments. Second, the present study population included a high proportion of  
16 patients with asymptomatic isolated distal DVT. Such a population could be expected to  
17 consist of patients with acute DVT, but isolated distal DVT without major symptoms could  
18 reflect minor thrombi, which should be interpreted with caution. Third, the adherence to the  
19 edoxaban treatment according to the study protocol was relatively low. Particularly, a  
20 substantial proportion of the patients in the 12-month edoxaban group discontinued edoxaban  
21 prematurely because of bleeding events or cancer progression. Fourth, there could be racial  
22 differences in the prevalence of hereditary thrombophilia, a low body weight, and types of  
23 cancer, as well as practice differences depending on the regions, such as the ultrasonography  
24 methodology. The generalizability of the present results should be carefully assessed. Finally,  
25 and most importantly, the present analysis was not a pre-specified analysis, but a post-hoc  
26 analysis conducted due to the clinical relevance regarding the numerically higher incidence

1 of major bleeding for the 12-month edoxaban treatment. Thus, the results should be  
2 interpreted cautiously as a hypothesis-generating exploratory analysis.

### 3 **Conclusions**

4 The net clinical benefit of the 12-month over 3-month edoxaban treatment was not  
5 significant; however, the 12-month compared to the 3-month treatment had a numerically  
6 lower incidence of NACE.

7

1    **Declarations**

2    **Acknowledgments:** This study was an investigator-initiated study with financial support from  
3    Daiichi Sankyo Co., Ltd. We are grateful to all staff, particularly the Clinical Events  
4    Committee, Data Safety Monitoring Committee, and Clinical Research Organization (MID,  
5    Inc. and Department of Cardiovascular Medicine, Graduate School of Medicine and Faculty  
6    of Medicine Kyoto University) for their thorough work, to all site personnel who helped to  
7    enroll participants, and to all health-care professionals who took care of our patients during  
8    this study protocol. We also appreciate Mr. John Martin for his grammatical assistance in  
9    writing the manuscript. Finally, we thank all of the participants, without whom this research  
10   would not have been possible.

11  
12   **Funding:** Funding was provided by Daiichi Sankyo Co., Ltd., which had no role in the study  
13   design, data collection, analysis, interpretation, or writing of the report.

14  
15   **Conflicts of interest:** Dr. Nishimoto received lecture fees from Bayer Healthcare,  
16   Bristol-Myers Squibb, Pfizer, and Daiichi-Sankyo. Dr. Yamashita received lecture fees from  
17   Bayer Healthcare, Bristol-Myers Squibb, Pfizer, and Daiichi-Sankyo, and grant support from  
18   Bayer Healthcare and Daiichi-Sankyo. Dr. Morimoto reports lecturer's fees from AstraZeneca,  
19   Bristol-Myers Squibb, Daiichi Sankyo, Japan Lifeline, Kowa, Pfizer and Tsumura;  
20   manuscript fees from Bristol-Myers Squibb and Pfizer; advisory board for Novartis and  
21   Teijin. Dr. Ogihara received lecture fees from Bayer Healthcare, Bristol-Myers Squibb, Pfizer,  
22   and Daiichi-Sankyo, and research funds from Bayer Healthcare and Daiichi-Sankyo. Dr.  
23   Dohi received lecture fees from Bayer Healthcare, Bristol-Myers Squibb, Pfizer, and  
24   Daiichi-Sankyo, and research funds from Daiichi-Sankyo. Dr. Ikeda N. received lecture fees  
25   from Bayer Healthcare, Bristol-Myers Squibb, and Daiichi-Sankyo. Dr. Tsubata received  
26   lecture fees from AstraZeneca, Chugai Pharmaceutical, Bristol-Myers Squibb, Kyowa Kirin,



1 Pfizer, Taiho Pharmaceutical, Takeda Pharmaceutical and Daiichi-Sankyo, and grant support  
2 from Daiichi-Sankyo, AstraZeneca and OnoPharmaceutical. Dr. Ikeda S. received lecture fees  
3 from Bayer Healthcare, Bristol-Myers Squibb and Daiichi-Sankyo. All other authors have  
4 reported that they have no relationships relevant to the contents of this paper to disclose.

5  
6 **Data availability:** The data, analytic methods, and study materials will not be made available  
7 to other researchers for purposes of reproducing the results or replicating the procedure.

8  
9 **Ethics approval and consent to participate:** The trial was conducted in accordance with the  
10 principles of the Declaration of Helsinki and was approved by the Kyoto University  
11 Institutional Review Board, along with the institutional review boards of all participating  
12 institutions.

13  
14 **Consent for publication:** All patients provided written informed consent.

15  
16 **Authors' contributions:** **Yuji Nishimoto:** Conceptualization, Methodology, Software, Formal  
17 analysis, Investigation, Writing - Original Draft; **Yugo Yamashita:** Conceptualization,  
18 Methodology, Software, Formal analysis, Investigation, Writing - Review and Editing;  
19 **Takeshi Morimoto:** Conceptualization, Methodology, Writing - Review and Editing;  
20 **Takeshi Kimura:** Conceptualization, Methodology, Writing - Review and Editing. All other  
21 authors contributed to the Investigation and Supervision. All authors read and approved the  
22 final manuscript.

## 1   **References**

- 2   1.       Gervaso L, Dave H, Khorana AA. Venous and Arterial Thromboembolism in  
3   Patients With Cancer: JACC: CardioOncology State-of-the-Art Review. *JACC CardioOncol.*  
4   2021;3:173–190.
- 5   2.       Lyon AR, López-Fernández T, Couch LS, Aznar MC, Boriani G, Cardinale D,  
6   Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF. 2022 ESC  
7   Guidelines on cardio-oncology developed in collaboration with the European Hematology  
8   Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO)  
9   and the International Cardio-Oncology Society (IC-OS). *Eur Heart J* 2022; 43: 4229–4361.
- 10  3.       Wang RC, Miglioretti DL, Marlow EC, Kwan ML, Theis MK, Bowles EJA,  
11  Greenlee RT, Rahm AK, Stout NK, Weinmann S, Smith-Bindman R. Trends in Imaging for  
12  Suspected Pulmonary Embolism Across US Health Care Systems, 2004 to 2016. *JAMA Netw*  
13  *Open.* 2020;3:e2026930.
- 14  4.       Mulder FI, Horváth-Puhó E, van Es N, van Laarhoven HWM, Pedersen L, Moik F,  
15  Ay C, Büller HR, Sørensen HT. Venous thromboembolism in cancer patients: a  
16  population-based cohort study. *Blood.* 2021;137:1959–1969.
- 17  5.       Mahajan A, Brunson A, Adesina O, Keegan THM, Wun T. The incidence of  
18  cancer-associated thrombosis is increasing over time. *Blood advances.* 2022; 6: 307–320.
- 19  6.       Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA,  
20  Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang T-F, Yeo E, Zhang  
21  G, Zwicker JJ, Weitz JJ, Büller HR, Hokusai VTE Cancer Investigators. Edoxaban for the  
22  Treatment of Cancer-Associated Venous Thromboembolism. *N Engl J Med.* 2018;378:615–  
23  624.
- 24  7.       Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn  
25  JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J,  
26  Poole CJ, Maraveyas A, Levine M. Comparison of an Oral Factor Xa Inhibitor With Low

- 1 Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results  
2 of a Randomized Trial (SELECT-D). *J Clin Oncol*. 2018;36:2017–2023.
- 3 8. McBane RD, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A,  
4 Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S,  
5 Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL. Apixaban and dalteparin in active  
6 malignancy-associated venous thromboembolism: The ADAM VTE trial. *J Thromb Haemost*.  
7 2020;18:411–421.
- 8 9. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, Cohen A,  
9 Bauersachs R, Brenner B, Torbicki A, Sueiro MR, Lambert C, Gussoni G, Campanini M,  
10 Fontanella A, Vescovo G, Verso M, Caravaggio Investigators. Apixaban for the Treatment of  
11 Venous Thromboembolism Associated with Cancer. *N Engl J Med*. 2020;382:1599–1607.
- 12 10. Kim S-A, Lee JH, Lee JY, Hwang H-G, Kim Y-K, Yhim H-Y, Hong J, Lee J-O,  
13 Bang S-M. Treatment and Bleeding Complications of Cancer-Associated Venous  
14 Thromboembolism: A Korean Population-Based Study. *Thromb Haemost*. 2022;122:2011–  
15 2018.
- 16 11. Nishimoto Y, Ohbe H, Matsui H, Nakajima M, Sasabuchi Y, Sato Y, Watanabe T,  
17 Yamada T, Fukunami M, Yasunaga H. Trends in Treatment Patterns and Outcomes of  
18 Patients With Pulmonary Embolism in Japan, 2010 to 2020: A Nationwide Inpatient  
19 Database Study. *J Am Heart Assoc*. 2023;12:e028981.
- 20 12. Nishimoto Y, Yamashita Y, Morimoto T, Saga S, Amano H, Takase T, Hiramori S,  
21 Kim K, Oi M, Akao M, Kobayashi Y, Toyofuku M, Izumi T, Tada T, Chen P-M, Murata K,  
22 Tsuyuki Y, Sasa T, Sakamoto J, Kinoshita M, Togi K, Mabuchi H, Takabayashi K,  
23 Yoshikawa Y, Shiomi H, Kato T, Makiyama T, Ono K, Sato Y, Kimura T, COMMAND  
24 VTE Registry Investigators. Predictive ability of modified Ottawa score for recurrence in  
25 patients with cancer-associated venous thromboembolism: From the COMMAND VTE  
26 Registry. *Thromb Res*. 2020;191:66–75.

- 1 13. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P,  
2 Huisman MV, Humbert M, Jennings CS, Jiménez D, Kucher N, Lang IM, Lankeit M,  
3 Lorusso R, Mazzolai L, Meneveau N, Ní Áinle F, Prandoni P, Pruszczyk P, Righini M,  
4 Torbicki A, Van Belle E, Zamorano JL, ESC Scientific Document Group. 2019 ESC  
5 Guidelines for the diagnosis and management of acute pulmonary embolism developed in  
6 collaboration with the European Respiratory Society (ERS). *Eur Heart J*. 2020;41:543–603.
- 7 14. Kakkos SK, Gohel M, Baekgaard N, Bauersachs R, Bellmunt-Montoya S, Black SA,  
8 Ten Cate-Hoek AJ, Elalamy I, Enzmann FK, Geroulakos G, Gottsäter A, Hunt BJ, Mansilha  
9 A, Nicolaides AN, Sandset PM, Stansby G, Esvs Guidelines Committee null, de Borst GJ,  
10 Bastos Gonçalves F, Chakfé N, Hinchliffe R, Kolh P, Koncar I, Lindholt JS, Tulamo R,  
11 Twine CP, Vermassen F, Wanhainen A, Document Reviewers null, De Maeseneer MG,  
12 Comerota AJ, Glociczki P, Kruij MJHA, Monreal M, Prandoni P, Vega de Ceniga M.  
13 Editor’s Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice  
14 Guidelines on the Management of Venous Thrombosis. *Eur J Vasc Endovasc Surg*.  
15 2021;61:9–82.
- 16 15. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL,  
17 Balaban EP, Flowers CR, Gates LE, Kakkar AK, Tempero MA, Gupta S, Lyman GH,  
18 Falanga A. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer:  
19 ASCO Guideline Update. *J Clin Oncol*. 2023;41:3063–3071.
- 20 16. Falanga A, Ay C, Di Nisio M, Gerotziakas G, Jara-Palomares L, Langer F,  
21 Lecumberri R, Mandala M, Maraveyas A, Pabinger I, Sinn M, Syrigos K, Young A, Jordan K,  
22 ESMO Guidelines Committee. Venous thromboembolism in cancer patients: ESMO Clinical  
23 Practice Guideline. *Ann Oncol*. 2023;34:452–467.
- 24 17. Nishimoto Y, Yamashita Y, Kim K, Morimoto T, Saga S, Amano H, Takase T,  
25 Hiramori S, Oi M, Akao M, Kobayashi Y, Toyofuku M, Izumi T, Tada T, Chen P-M, Murata  
26 K, Tsuyuki Y, Sasa T, Sakamoto J, Kinoshita M, Togi K, Mabuchi H, Takabayashi K,

- 1 Yoshikawa Y, Shiomi H, Kato T, Makiyama T, Ono K, Sato Y, Kimura T, COMMAND  
2 VTE Registry Investigators. Risk Factors for Major Bleeding During Anticoagulation  
3 Therapy in Cancer-Associated Venous Thromboembolism - From the COMMAND VTE  
4 Registry. *Circ J*. 2020;84:2006–2014.
- 5 18. Yamashita Y, Morimoto T, Muraoka N, Oyakawa T, Umetsu M, Akamatsu D,  
6 Nishimoto Y, Sato Y, Takada T, Jujo K, Minami Y, Ogihara Y, Dohi K, Fujita M, Nishikawa  
7 T, Ikeda N, Hashimoto G, Otsui K, Mori K, Sueta D, Tsubata Y, Shoji M, Shikama A, Hosoi  
8 Y, Tanabe Y, Chatani R, Tsukahara K, Nakanishi N, Kim K, Ikeda S, Mo M, Yoshikawa Y,  
9 Kimura T, ONCO DVT Study Investigators. Edoxaban for 12 Months Versus 3 Months in  
10 Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An  
11 Open-Label, Multicenter, Randomized Clinical Trial. *Circulation*. 2023;148:1665–1676.
- 12 19. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the  
13 Scientific and Standardization Committee of the International Society on Thrombosis and  
14 Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic  
15 medicinal products in non-surgical patients. *J Thromb Haemost*. 2005;3:692–694.
- 16 20. Bleker SM, Brekelmans MPA, Eerenberg ES, Cohen AT, Middeldorp S, Raskob G,  
17 Büller HR. Clinical impact of major bleeding in patients with venous thromboembolism  
18 treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data  
19 meta-analysis. *Thromb Haemost*. 2017;117:1944–1951.
- 20 21. Steg PG, Ducrocq G, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Lip GYH,  
21 Oldgren J, Ten Berg JM, Cannon CP. Dabigatran Dual Therapy Versus Warfarin Triple  
22 Therapy Post PCI in Patients With Atrial Fibrillation. *J Am Coll Cardiol*. 2020;75:238–240.
- 23 22. Klok FA, Huisman MV. How I assess and manage the risk of bleeding in patients  
24 treated for venous thromboembolism. *Blood*. 2020;135:724–734.
- 25 23. Steg PG, Bhatt DL. Is There Really a Benefit to Net Clinical Benefit in Testing  
26 Antithrombotics? *Circulation*. 2018;137:1429–1431.

- 1 24. Nieto JA, Solano R, Ruiz-Ribó MD, Ruiz-Gimenez N, Prandoni P, Kearon C,  
2 Monreal M, Riete Investigators. Fatal bleeding in patients receiving anticoagulant therapy for  
3 venous thromboembolism: findings from the RIETE registry. *J Thromb Haemost.*  
4 2010;8:1216–1222.
- 5 25. Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K, Oi M, Akao M,  
6 Kobayashi Y, Toyofuku M, Izumi T, Tada T, Chen P-M, Murata K, Tsuyuki Y, Saga S, Sasa  
7 T, Sakamoto J, Kinoshita M, Togi K, Mabuchi H, Takabayashi K, Watanabe H, Shiomi H,  
8 Kato T, Makiyama T, Ono K, Kimura T, COMMAND VTE Registry Investigators. Influence  
9 of Baseline Platelet Count on Outcomes in Patients With Venous Thromboembolism (from  
10 the COMMAND VTE Registry). *Am J Cardiol.* 2018;122:2131–2141.
- 11 26. Ito S, Inoko M, Yamashita Y, Morimoto T, Kimura T, COMMAND VTE Registry-2  
12 Investigators. Thrombocytopenia and bleeding events in patients with venous  
13 thromboembolism. *Eur J Intern Med.* 2024;S0953-6205(24)00013-X.
- 14 27. Angelini DE, Radivoyevitch T, McCrae KR, Khorana AA. Bleeding incidence and  
15 risk factors among cancer patients treated with anticoagulation. *Am J Hematol.* 2019;94:780–  
16 785.
- 17  
18  
19  
20  
21  
22  
23  
24  
25  
26

1

2

### 3 **Figure Legends**

#### 4 **Figure 1. The Kaplan-Meier curves for (A) NACE-1 and (B) NACE-2 comparing the** 5 **12-month and 3-month edoxaban treatment groups**

6 Time-to-event curves for (A) NACE-1 (symptomatic recurrent VTE, VTE-related death, or  
7 major bleeding) for 12 months and (B) NACE-2 (symptomatic recurrent VTE, VTE-related  
8 death, asymptomatic recurrent VTE, or all clinically relevant bleeding) with a weight of  
9 bleeding events of 1.0. Asymptomatic recurrent VTE was defined as the appearance of new  
10 or worsening thrombus images in the pulmonary arteries and deep veins on imaging tests  
11 (ultrasonography of lower limb vein system, computed tomography examination, pulmonary  
12 perfusion scintigraphy, pulmonary angiography, and venography) that did not match the  
13 definition of a symptomatic VTE recurrence and was not associated with new or worsening  
14 symptoms. All clinically relevant bleeding included major bleeding and clinically relevant  
15 nonmajor bleeding, which were defined according to the criteria of the International Society  
16 on Thrombosis and Hemostasis.

17 NACE, net adverse clinical events; VTE, venous thromboembolism

18

#### 19 **Figure 2. Subgroup analyses for net adverse clinical event-1**

20 Net adverse clinical event-1 was a composite of symptomatic recurrent venous  
21 thromboembolism, venous thromboembolism-related death, or major bleeding with a weight  
22 of bleeding events of 1.0. The odds ratios with 95% CIs for the net adverse clinical events  
23 with the 12-month over 3-month edoxaban treatment are described in the prespecified  
24 clinically relevant subgroups as well as in the subgroups according to the symptom at  
25 diagnosis. The 95% CIs have not been adjusted for multiple comparisons.

26 CI, confidence interval; VTE, venous thromboembolism

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

**Figure 3. The net clinical benefit of the 12-month over 3-month edoxaban treatment at different bleeding weights: (A) for NACE-1 and (B) for NACE-2**

The net clinical benefit of the 12-month over 3-month edoxaban treatment was calculated as follows: incidence of thrombotic events (3-month edoxaban treatment – 12-month edoxaban treatment) + incidence of bleeding events (3-month edoxaban treatment – 12-month edoxaban treatment) × bleeding weight.

NACE-1 was a composite endpoint of symptomatic recurrent VTE, VTE-related death, or major bleeding at 12 months. NACE-2 was a composite endpoint of symptomatic recurrent VTE, VTE-related death, asymptomatic recurrent VTE, or all clinically relevant bleeding at 12 months.

NACE, net adverse clinical events; VTE, venous thromboembolism





**Table 1. Baseline patient characteristics**

	<b>Overall (N=601)</b>	<b>12-month edoxaban (N=296)</b>	<b>3-month edoxaban (N=305)</b>
<b>Baseline characteristics</b>			
Age, years	70.8±9.9	71.6±9.4	70.1±10.3
Men, No. (%)	167 (28)	94 (32)	73 (24)
Body weight, kg	55.5±11.9	56.3±12.1	54.8±11.6
Body mass index, kg/m <sup>2</sup>	22.5±4.1	22.7±4.0	22.4±4.1
Symptoms at baseline, No. (%)	122 (20)	53 (18)	69 (23)
Site of thrombosis, No. (%)			
Bilateral, No. (%)	223 (37)	118 (40)	105 (34)
Right side, No. (%)	154 (26)	73 (25)	81 (27)
Left side, No. (%)	224 (37)	105 (35)	119 (39)
Standard dose of edoxaban (60 mg per day), No. (%)	151 (25)	80 (27)	71 (23)
Lower dose of edoxaban (30 mg per day), No. (%)	450 (75)	216 (73)	234 (77)
<b>Cancer status</b>			
Metastatic disease, No. (%)	147 (24)	67 (23)	80 (26)
Recurrent cancer, No. (%)	65 (11)	31 (10)	34 (11)
ECOG performance status, No. (%)			
0	311 (52)	161 (54)	150 (49)
1	181 (30)	78 (26)	103 (34)
≥2	109 (18)	57 (19)	52 (17)
<b>Comorbidities</b>			
Hypertension, No. (%)	263 (44)	133 (45)	130 (43)
Diabetes, No. (%)	101 (17)	54 (18)	47 (15)
Heart failure, No. (%)	10 (2)	7 (2.4)	3 (1.0)
History of stroke, No. (%)	27 (4)	14 (4.7)	13 (4.3)
History of VTE, No. (%)	33 (5)	20 (6.8)	13 (4.3)
History of major bleeding, No. (%)	23 (4)	7 (2.4)	16 (5.3)
Transient risk factors for VTE, No. (%)	151 (25)	80 (27)	71 (23)
Recent surgery within 2 months, No. (%)	85 (14)	41 (14)	44 (14)
<b>Laboratory tests at diagnosis</b>			
Creatinine clearance ≤50 ml/min, No. (%)	131 (22)	69 (23)	62 (20)
Anemia, No. (%)	402 (67)	199 (67)	203 (67)
Platelet count <100,000 per µl, No. (%)	31 (5)	12 (4.1)	19 (6.2)
D-dimer, µg/mL	5.0 (2.2-10.8)	5.2 (2.2-10.8)	4.7 (2.3-11.3)
<b>Concomitant medication</b>			
Antiplatelet, No. (%)	48 (8)	27 (9.1)	21 (6.9)
Steroid, No. (%)	77 (13)	34 (11)	43 (14)
Statins, No. (%)	134 (22)	71 (24)	63 (21)

1 Values are expressed as the mean  $\pm$  standard deviation, median (interquartile range), or number with the percentage.  
2 In the study protocol, edoxaban was recommended to be administered at a reduced dose of 30 mg once daily in patients  
3 with a creatinine clearance of 30 to 50 ml per minute or a body weight of 60 kg or less or in those receiving concomitant  
4 treatment with potent P-glycoprotein inhibitors. ECOG performance status values range from 0 to 4, with higher values  
5 indicating greater disability. Transient risk factors for VTE included recent surgery, recent immobilization, long-distance  
6 travel, central venous catheter use, pregnancy or puerperium, recent leg trauma, fracture or burn, severe infection, and  
7 estrogen use. Anemia was diagnosed if the hemoglobin value was  $<13$  g/dL for men and  $<12$  g/dL for women. The  
8 D-dimer values were missing in 34 patients.  
9 ECOG, Eastern Cooperative Oncology Group; SMD, standardized mean difference; VTE, venous thromboembolism

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

1

**Table 2. Clinical outcomes at 12 months\***

	12-month edoxaban (N=296)	3-month edoxaban (N=305)	Odds ratio (95% CI)
<b>Net adverse clinical event-1†</b>	30 (10.1)	42 (13.8)	0.71 (0.43-1.16)
Symptomatic VTE or VTE-related death, No. (%)	3 (1.0)	22 (7.2)	0.13 (0.03-0.44)
Major bleeding, No. (%)‡	28 (9.5)	22 (7.2)	1.34 (0.75-2.41)
<b>Net adverse clinical event-2†</b>	69 (23.3)	95 (31.1)	0.67 (0.47-0.97)
Symptomatic VTE or VTE-related death, No. (%)	3 (1.0)	22 (7.2)	0.13 (0.03-0.44)
Asymptomatic recurrent VTE, No. (%)§	23 (7.8)	46 (15.1)	0.47 (0.28-0.80)
All clinically relevant bleeding, No. (%)‡	53 (17.9)	41 (13.4)	1.40 (0.90-2.19)

2 \*The analyses were performed for the full analysis set based on the intention-to-treat approach, which included all the  
3 patients who had undergone randomization after excluding patients who withdrew consent. For patients who did not  
4 experience an event, the time to the first event was censored at day 365, or the last day the patient had a complete  
5 assessment for study outcomes, whichever came first. We calculated the odds ratios using the logistic regression model  
6 along with the corresponding 95% CIs for all clinical endpoints, which have not been adjusted for multiple comparisons.


7 †Net adverse clinical event-1 was a composite of symptomatic recurrent VTE, VTE-related death, or major bleeding with  
8 a weight of bleeding events of 1.0. Net adverse clinical event-2 was a composite of symptomatic recurrent VTE,  
9 VTE-related death, asymptomatic recurrent VTE§, or all clinically relevant bleeding‡ with a weight of bleeding events of  
10 1.0.

11 ‡All clinically relevant bleeding included major bleeding and clinically relevant nonmajor bleeding, which were defined  
12 according to the criteria of the International Society on Thrombosis and Hemostasis.


13 §Asymptomatic recurrent VTE was defined as an appearance of new or worsening thrombus images in the pulmonary  
14 arteries and deep veins on imaging tests (ultrasonography of lower limb vein system, computed tomography examination,  
15 pulmonary perfusion scintigraphy, pulmonary angiography, and venography) that did not match the definition of a  
16 symptomatic VTE recurrence and were not associated with new or worsening symptoms.

17 CI, confidence interval; VTE, venous thromboembolism

18



	0 day	60 days	90 days	120 days	180 days	365 days
<b>12-month edoxaban</b>						
N of patients with event		14	16	18	21	30
N of patients at risk	296	271	265	258	243	209
Cumulative incidence		4.8%	5.5%	6.2%	7.3%	11.0%
<b>3-month edoxaban</b>						
N of patients with event		15	18	23	29	42
N of patients at risk	305	277	268	261	245	204
Cumulative incidence		5.0%	6.0%	7.8%	9.9%	15.1%



	0 day	60 days	90 days	120 days	180 days	365 days
<b>12-month edoxaban</b>						
N of patients with event		30	36	46	52	69
N of patients at risk	296	257	247	234	217	180
Cumulative incidence		10.2%	12.3%	15.9%	18.1%	24.8%
<b>3-month edoxaban</b>						
N of patients with event		29	36	50	59	95
N of patients at risk	305	264	252	235	219	170
Cumulative incidence		9.6%	12.0%	16.9%	20.2%	34.4%

